- Details
- Ashish Kamat is joined by Colin Dinney to discuss the results of the SUO-CTC Phase 3 Trial of nadofaragene firadenovec for patients with non-muscle invasive bladder cancer unresponsive to BCG. Dr. Dinney presents slides and discusses how most NMIBC patients recur despite BCG therapy, and there is an unmet need for therapies in patients' refractory to BCG. Previously, Nadofaragene firadenovec was t...
|
- Details
- Anne Schuckman, MD, MBBS, presents a summary of her plenary session presentation from the AUA 2020 live virtual conference on benefits of Blue Light Cystoscopy (BLC ® ) with Cysview ® , in a conversation with Ashish Kamat, MD. Dr. Schuckman details how Cysview can be used to visualize bladder tumors and highlights benefits arising from this technique including an increased ability to resect the tu...
|
- Details
- Ashish Kamat is joined by Veeru Kasivisvanathan, Kevin Gallagher, and Nikita Bhatt — members of the global research group British Urology Researchers in Surgical Training (BURST) — discussing the global RESECT study. Transurethral REsection and Single instillation intravesical chemotherapy Evaluation in bladder Cancer Treatment (RESECT) Improving quality in TURBT surgery. The RESECT study investig...
|
- Details
- Ashish Kamat, MD, MBBS is joined by Sima Porten, MD, MPH and Joshua Meeks, MD, PhD, panelist in the American Urological Association (AUA) Guidelines Case-Based Panel Discussion on Non-muscle and Muscle Invasive Bladder Cancer AUA 2020 plenary presentation. They provide their perspectives on bladder cancer patient guidelines-based management and the specific management of bladder cancer patients. B...
|
- Details
- Stephen Williams discusses the macro and microeconomics of using blue light cystoscopy with CYSVIEW ® in nonmuscle invasive bladder cancer compared to white light cystoscopy alone. Dr. Williams notes that cancer care is expected to increase from $158 to $174 billion dollars between 2010 and 2020 due to increasing cancer incidence, improved survival outcomes, and an expanding healthcare market. Cos...
|
- Details
- Alicia Morgans and Sam Chang discuss the Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer AUA/ASCO/ASTRO/SUO Guidelines. Dr. Chang, a member of the bladder cancer guidelines committee, notes that while the guidelines are in the process of being updated since these were last updated in 2017, they serve as an algorithm for all clinicians on how to evaluate patients and risk stratification....
|
- Details
- Ashish Kamat is joined by Hugh Mostafid for a discussion on trans urethral resection of bladder tumor (TURBT) improvement, and the imperfections that impede TURBT success. Dr. Mostafid discusses current methods to optimize TURBT and highlights ways to improve surgical outcomes. He shares that by reviewing the current technique and outcomes and employing better imaging and instrumentation, TURBT ca...
|
- Details
- Ashish Kamat is joined by Wassim Kassouf, an expert in the bladder cancer field on Bacillus Calmette-Guérin unresponsive disease. Together they discuss the different treatment options in these patients, how the shortage of BCG will affect patient samples in clinical studies, and how to counsel patients with BCG-unresponsive carcinoma in situ. Biographies: Wassim Kassouf, MD, CM, FRCSC, is a Profes...
|
- Details
- Trinity Bivalacqua joins Ashish Kamat to discuss the role of blue light cystoscopy in bladder cancer treatment, specifically regarding non-muscle invasive disease. Dr. Bivalacqua emphasizes how risk stratification allows for personalization of care and highlights a case study of a patient with high-risk non-muscle invasive bladder cancer. Dr. Bivalacqua also explains how blue light cystoscopy can...
|
- Details
- Joining Alicia Morgans at ASCO GU is Arjun Balar, a bladder cancer expert at New York University, who speaks to the most recent clinical trials and the future direction of available regimens regarding bladder preservation protocols. For the past 30 years, muscle-invasive urothelial cancer patients have been given two options for treatment: radical cystectomy or cisplatinum. With the more recent av...
|
